The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
The safety of calcium channel blockers during pregnancy: A prospective, multicenter, observational study
Abstract
Objective To assess the safety of calcium channel blockers during the first trimester of pregnancy.Study design A multicenter (n=11), prospective observational study of the European Network of Teratology Information Services (ENTIS). The rate of major birth defects was compared between a cohort of pregnant women exposed to calcium channel blockers during the first trimester (n=299) and a control group not exposed to potential teratogens (n=806).Results Major birth defects were not more common in the study group than in the control group. Birth weight was significantly lower in exposed term newborns. There were more preterm infants in the study group than in the control group (23.8% vs. 6.5%). These adverse effects are more likely due to the underlying disease than to the medication.Conclusion This study suggests that calcium channel blockers during the first trimester of pregnancy do not represent a major teratogenic risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the calcium channel blockers the experience is greatest with verapamil which overall appear to be relatively safe.405”
From European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE) (2017) · cites this paper as [405]
Citations
Cites
Martindale: the complete drug reference
(2005) · Choice Reviews Online · doi:10.5860/choice.42-6228 · Cited by 2,684
Guidelines for case classification for the national birth defects prevention study
Rasmussen, S. A., Olney, R. S., Holmes, L. B., Lin, A. E., Keppler‐Noreuil, K. M., & Moore, C. A. (2003) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.10012 · Cited by 581
Vitamin K antagonists and pregnancy outcome
Hannemann, D., Meister, R., Éléfant, É., Paulus, W. E., Vial, T., Reuvers, M., Robert‐Gnansia, E., Arnon, J., Santis, M. D., Clementi, M., et al. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-02-0108 · Cited by 208
The safety of calcium channel blockers in human pregnancy: A prospective, multicenter cohort study
Magee, L. A., Schick, B., Donnenfeld, A. E., Sage, S. R., Conover, B., Cook, L. P., McElhatton, P. R., Schmidt, M. A., & Koren, G. (1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70307-1 · Cited by 202
Phenotypic abnormalities: Terminology and classification
Merks, J. H. M., van Karnebeek, C., Caron, H. N., & Hennekam, R. C. M. (2003) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.20249 · Cited by 118
Simán, C. M., Groot, A. C. G., Wisse, B., & Eriksson, U. J. (2000) · Teratology · doi:10.1002/(sici)1096-9926(200005)61:5 · Cited by 96
Post-marketing surveillance system for drugs in pregnancy—15 years experience of ENTIS
Schaefer, C., Hannemann, D., & Meister, R. (2005) · Reproductive Toxicology · doi:10.1016/j.reprotox.2005.03.012 · Cited by 63
Danielsson, B. R. G., Reiland, S., Rundqvist, E., & Danielson, M. (1989) · Teratology · doi:10.1002/tera.1420400407 · Cited by 62
Sørensen, H. T., Czeizel, A. E., Rockenbauer, M., Steffensen, F. H., & Olsen, J. (2001) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1034/j.1600-0412.2001.d01-4.x · Cited by 46
Pathogenesis of retinoic acid-induced ear malformations in a primate model
Wei, X. P., Makori, N., Peterson, P. E., Hummler, H., & Hendrickx, A. G. (1999) · Teratology · doi:10.1002/(sici)1096-9926(199908)60:2 · Cited by 45
Flagged first, then by citations
Research works printed but not linked: 3
- Sørensen, 1998, Pregnancy outcome in women exposed to calcium channel blockers, Reprod Toxicol, 12, 383
- Tabacova, 2002, Developmental abnormalities reported to FDA in association with nifedipine treatment in pregnancy, Teratology, 65, 368
- Yoshida, 1989, Hyperphalangism induced by Ca-blockers in rat fetuses, Teratology, 40, 668
Cited by
Sorted by citations
Items 101–103 of 103
Semins, M. J., & Matlaga, B. R. (2012) · Springer eBooks · doi:10.1007/978-3-642-28732-9_15
Atrial Fibrillation and Atrial Flutter in Pregnancy: Epidemiology, Pathophysiology, and Management
Li‐Barton, J. Y., Watkins, V. Y., Snow, S. C., Kuller, J. A., & Federspiel, J. J. (2026) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001538
Al‐Taie, A., & Ayhan, Y. E. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00755-3
“Using CCBs during the first trimester of pregnancy does not appear to pose a significant risk of teratogenic effects [ 51, 52].”
Metadata
- Authors
- Weber-Schoendorfer, C., Hannemann, D., Meister, R., Eléfant, E., Cuppers-Maarschalkerweerd, B., Arnon, J., Vial, T., Rodriguez-Pinilla, E., Clementi, M., Robert-Gnansia, E., De Santis, M., Malm, H., Dolivo, A., & Schaefer, C.
- Affiliations
- Berliner Hochschule für Technik (DE)
- Israel Ministry of Health (IL)
- Hospices Civils de Lyon (FR)
- University of Padua (IT)
- Venue
- Reproductive Toxicology
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 26
- Issue
- 1
- Pages
- 24-30
- ISSN
- 0890-6238 (ISSN-L)
- OpenAlex
- W2027351405
- Cited by
- 104
- References
- 15
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 8 · 2022: 3 · 2021: 7 · 2020: 5 · 2019: 18 · 2018: 10 · 2017: 4 · 2016: 4 · 2015: 5 · 2014: 6 · 2013: 3 · 2012: 5
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Reproductive Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Rivm (National Institute for Public Health and the Environment) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Bundesinstitut für Arzneimittel und Medizinprodukte
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
- Keywords
- calcium channel blockers, pregnancy, first trimester, teratogenicity, congenital malformations, birth weight, preterm birth, drug safety in pregnancy
- MeSH terms
- Abnormalities, Drug-Induced, Abortion, Spontaneous, Adolescent, Adult, Birth Weight, Calcium Channel Blockers, Europe, Female, Humans, Infant, Low Birth Weight, Infant, Newborn, Israel, Middle Aged, Pregnancy, Pregnancy Trimester, First, Prospective Studies, Premature Birth
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
